Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

28/04/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, with results in only three hours. Ensure they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2026-03/CRC%20Oncologist%20-%20Leaflet%20-%20Mar2026.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
The content of this post is only applicable to Idylla™ KRAS & NRAS-BRAF Mutation Tests and Idylla™ MSI & CDx MSI Tests which are CE-marked in Europe; Idylla™ MSI Test which is cleared in the US under K211181 for Lynch Syndrome; and Idylla™ CDx MSI Test which is approved in the US under P250005. Idylla™ KRAS & NRAS-BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

23/04/2026

📣 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 (𝗜𝗩𝗗𝗥*)
✔️ Companion diagnostic (𝗖𝗗𝘅) to identify adult patients with MSI-H mCRC who may benefit from treatment with 𝗢𝗣𝗗𝗜𝗩𝗢® (nivolumab) + 𝗬𝗘𝗥𝗩𝗢𝗬® (ipilimumab)
✔️ Sample to result in ~𝟭𝟱𝟬 𝗺𝗶𝗻 without the need for sample batching
✔️ Concordance rate of 𝟵𝟴.𝟱𝟳% against OncoMate™ MSI Dx Analysis System
✔️ Directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, 𝗻𝗼 𝗽𝗮𝗶𝗿𝗲𝗱 tissue samples needed

𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 👉 https://lnkd.in/ehE7tyAt

*𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘮𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴. 𝘖𝘗𝘋𝘐𝘝𝘖® 𝘢𝘯𝘥 𝘠𝘌𝘙𝘝𝘖𝘠® 𝘢𝘳𝘦 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬𝘴 𝘰𝘧 𝘉𝘳𝘪𝘴𝘵𝘰𝘭-𝘔𝘺𝘦𝘳𝘴 𝘚𝘲𝘶𝘪𝘣𝘣 𝘊𝘰𝘮𝘱𝘢𝘯𝘺.

21/04/2026

📅 21 April marks Acute Myeloid Leukemia (AML) World Awareness Day

On this day, we come together to help raise awareness and educate people on AML 📣 AML is a rare and aggressive cancer of the blood 🩸 and bone marrow 🦴.

💡 Did you know that...
- mutations in isocitrate dehydrogenase 1 (IDH1) are observed in 7-14% of adult AML patients*
- mutations in isocitrate dehydrogenase 2 (IDH2) are observed in 8-19% of AML patients*

Check out our Idylla™ IDH1-2 Mutation Assay Kit (RUO**) 👀 https://www.biocartis.com/en/research/research-assays/idylla-idh1-2-mutation-assay-kit?utm_source=facebook&utm_medium=social&utm_campaign=2104_mutation-assay-kit

*References: https://www.biocartis.com/en/references?utm_source=facebook&utm_medium=social&utm_campaign=2104_references

**For Research Use Only (RUO), not for use in diagnostic procedures.
Know AML

14/04/2026

𝟯...𝟮...𝟭... 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝗱 𝗶𝗻 𝗡𝗲𝗽𝗮𝗹 🚀
Until now, oncology-grade molecular testing hasn’t been locally available in Nepal. 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝘁𝗵𝗮𝘁.

⏱️ By bringing 𝗳𝗮𝘀𝘁, 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 into a format that fits Nepal’s healthcare reality, it enables something powerful… For the first time, the test that should guide the very 𝗳𝗶𝗿𝘀𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗰𝗮𝗻 𝗵𝗮𝗽𝗽𝗲𝗻 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝗼𝗻-𝘀𝗶𝘁𝗲, 𝗶𝗻 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀.

🤝 We are proud to partner with Web Trading Concern Pvt. Ltd. to help make molecular biomarker testing accessible to patients across Nepal.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™ 👉 https://www.biocartis.com/en/meet-idylla

𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘗𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘪𝘴 𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙), 𝘭𝘪𝘴𝘵𝘦𝘥 𝘢𝘴 𝘢 𝘤𝘭𝘢𝘴𝘴 𝘐𝘐 𝘥𝘦𝘷𝘪𝘤𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚 𝘶𝘯𝘥𝘦𝘳 𝘦𝘴𝘵𝘢𝘣𝘭𝘪𝘴𝘩𝘮𝘦𝘯𝘵 𝘳𝘦𝘨𝘪𝘴𝘵𝘳𝘢𝘵𝘪𝘰𝘯 3009972873, 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘮𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴.

13/04/2026

📍 𝗪𝗵𝗲𝗿𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗺𝗲𝗲𝘁𝘀 𝗵𝗶𝘀𝘁𝗼𝗿𝘆, a truly unique setting for today’s symposium.

Today we’re participating in the 𝗣𝗠𝗠𝗣 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 from the 𝗖𝗮𝘁𝗵𝗲𝗱𝗿𝗮𝗹 𝗼𝗳 𝗦𝗮𝗶𝗻𝘁 𝗣𝗿𝗼𝗰𝗼𝗹𝘂𝘀 𝗠𝗮𝗿𝘁𝘆𝗿 in Pozzuoli, Italy!

A big thank you to Dr. Elisa Melucci (IFO – Istituto Regina Elena, Rome) for her 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝗳𝘂𝗹 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝗣𝗢𝗟𝗘 and its role in endometrial cancer. 𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? Discover the Idylla™ POLE-POLD1 Mutation Assay (RUO**)👉 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay

* 𝘗𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘪𝘰𝘯 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘦𝘥 𝘣𝘺 𝘉𝘪𝘰𝘤𝘢𝘳𝘵𝘪𝘴
** 𝘍𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴

13/04/2026

🌸☀️𝐒𝐩𝐫𝐢𝐧𝐠 𝐜𝐥𝐞𝐚𝐧𝐢𝐧𝐠 𝐢𝐬𝐧’𝐭 𝐣𝐮𝐬𝐭 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐡𝐨𝐦𝐞, 𝐲𝐨𝐮𝐫 𝐥𝐚𝐛 𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐬 𝐚 𝐫𝐞𝐟𝐫𝐞𝐬𝐡 𝐭𝐨𝐨!

Is your lab still dealing with cluttered workstations and complex workflows?
Declutter your lab. Simplify your workflow. THINK IDYLLA™:
✅ < 3 minutes hands-on time
✅ compact & fully automated system
✅ molecular biomarker results in only 3 hours

🔗 Get more info now: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1304_meet-idylla

10/04/2026

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests and assays enabling rapid biomarker results in lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer samples.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1004_meet-idylla

07/04/2026

𝐓𝐨𝐝𝐚𝐲 𝐢𝐬 𝐖𝐨𝐫𝐥𝐝 𝐇𝐞𝐚𝐥𝐭𝐡 𝐃𝐚𝐲 🌎
This year’s theme, “𝐓𝐨𝐠𝐞𝐭𝐡𝐞𝐫 𝐟𝐨𝐫 𝐡𝐞𝐚𝐥𝐭𝐡. 𝐒𝐭𝐚𝐧𝐝 𝐰𝐢𝐭𝐡 𝐬𝐜𝐢𝐞𝐧𝐜𝐞”, celebrates the power of science in improving healthcare outcomes for everyone.

At Biocartis, we help enable 𝐮𝐧𝐢𝐯𝐞𝐫𝐬𝐚𝐥 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞, making molecular testing fast, easy, and ready for any lab. We thank our Idylla™ users, who bring 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞, 𝐬𝐜𝐢𝐞𝐧𝐜𝐞-𝐝𝐫𝐢𝐯𝐞𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐭𝐨 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐡𝐞𝐥𝐩 𝐞𝐧𝐬𝐮𝐫𝐞 𝐨𝐩𝐭𝐢𝐦𝐚𝐥 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 🙏

👉 Meet Idylla™: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0704_meet-idylla

02/04/2026

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗮𝘁 𝘁𝗵𝗲 #𝗣𝗠𝗠𝗣 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲, 𝗳𝗼𝗰𝘂𝘀𝗶𝗻𝗴 𝗼𝗻 𝗣𝗢𝗟𝗘 𝗶𝗻 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿!
📅 Monday 13 April, 10:30 AM (CEST)
📍 PMMP Conference, Naples, Italy
🎤 Dr. Elisa Melucci (IFO – Istituto Regina Elena, Rome)*
🗣️ Italian

𝗚𝗲𝘁 𝗺𝗼𝗿𝗲 𝗶𝗻𝗳𝗼 👉https://educational.siapecservizi.it/images/congressi/279/programma.pdf

*𝘗𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘪𝘰𝘯 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘦𝘥 𝘣𝘺 𝘉𝘪𝘰𝘤𝘢𝘳𝘵𝘪𝘴.

01/04/2026

𝐖𝐞 𝐥𝐨𝐯𝐞 𝐚 𝐠𝐨𝐨𝐝 𝐀𝐩𝐫𝐢𝐥 𝐅𝐨𝐨𝐥'𝐬 𝐣𝐨𝐤𝐞, 𝐛𝐮𝐭 𝐰𝐡𝐞𝐧 𝐢𝐭 𝐜𝐨𝐦𝐞𝐬 𝐭𝐨 𝐈𝐝𝐲𝐥𝐥𝐚™, 𝐰𝐞’𝐫𝐞 𝐧𝐨𝐭 𝐟𝐨𝐨𝐥𝐢𝐧𝐠 𝐚𝐫𝐨𝐮𝐧𝐝 😉
With Idylla™, there are no tricks, no complexities, and no room for error — just fast, accurate, and fully automated testing that delivers reliable results ⏱️

👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0104_meet-idylla

31/03/2026

As comes to an end, we must not forget that the fight against CRC continues every day 💪

At Biocartis, we are dedicated to delivering fast & accurate molecular diagnostics to enable improvement of mCRC patient outcomes*. With Idylla™, biomarkers like , , , and are detected in ⏱️ONLY 3 HOURS⏱️, enabling immediate decisions for immunotherapy and targeted therapies. This rapid turnaround time ✔️reduces delays, ✔️alleviates patient anxiety, and ✔️ensures patients immediately get personalized care.
𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 👀 https://www.biocartis.com/en/oncology/for-oncologists/idylla-for-colorectal-cancer?utm_source=facebook&utm_medium=social&utm_campaign=3103_idylla-for-colorectal-cancer

💪 Let’s keep the momentum going beyond March and continue striving for better outcomes for every patient.

*The content of this post only applies to the Idylla™ KRAS & NRAS-BRAF Tests which are CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. These Tests are not available in the US, but are for Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ CDx MSI Test is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) (A0220/6) and approved in the US under P250005 (A0220/6). Idylla™ MSI Test is CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC (A0100/6) and cleared in the US under K211181 for Lynch Syndrome (A0160/6).

25/03/2026

📣 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 (𝗜𝗩𝗗𝗥*)
✔️ Companion diagnostic (𝗖𝗗𝘅) to identify adult patients with MSI-H mCRC who may benefit from treatment with 𝗢𝗣𝗗𝗜𝗩𝗢® (nivolumab) + 𝗬𝗘𝗥𝗩𝗢𝗬® (ipilimumab)
✔️ Sample to result in ~𝟭𝟱𝟬 𝗺𝗶𝗻 without the need for sample batching
✔️ Concordance rate of 𝟵𝟴.𝟱𝟳% against OncoMate™ MSI Dx Analysis System
✔️ Directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, 𝗻𝗼 𝗽𝗮𝗶𝗿𝗲𝗱 tissue samples needed

𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-cdx-msi-test

*𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘮𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴. 𝘖𝘗𝘋𝘐𝘝𝘖® 𝘢𝘯𝘥 𝘠𝘌𝘙𝘝𝘖𝘠® 𝘢𝘳𝘦 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬𝘴 𝘰𝘧 𝘉𝘳𝘪𝘴𝘵𝘰𝘭-𝘔𝘺𝘦𝘳𝘴 𝘚𝘲𝘶𝘪𝘣𝘣 𝘊𝘰𝘮𝘱𝘢𝘯𝘺.

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.